Richard Atkins

Richard Atkins is a senior contributor at Tech Insider covering online media, online travel, and video games. Richard has been with Tech Insider covering companies in these industries since 2011 and has authored numerous industry reports, including "Internet Video: Field of Dreams or Nightmare on Elm Street," "The Next Leg of Online Travel," and "Pwned: How Casual Games Changed The Gaming Landscape." Atkins was recognized as the No. 2 stock picker and earnings estimator in the 2011 Financial Times / StarMine Internet & Catalog Retail category and was ranked in the 2010 Wall Street Journal "Best On The Street" for the Leisure Goods & Services category.

Biotechnology Stockmarket Biotech

Biotech Stock Update: Keryx Falls after Ferric Citrate’s Tests

The FDA has approved Keryx Biopharmaceuticals, Inc’s (KERX) ferric citrate to control serum phosphorus levels in patients suffering from chronic kidney disease (CKD) on dialysis. However, the news adversely affected the stock price, which fell more than 5%, as the drug was approved with several warnings. Ferric citrate is not recommended for patients with an…

Read More

Stock in News: Microsoft (NASDAQ MSFT) Goes into Cloud

Wednesday, before the opening day of the International Broadcasting Convention (IBC), Microsoft Corp (Nasdaq MSFT) announced new cloud-first media services, including HD-quality live streaming that supports today’s most popular devices and platforms, end-to-end content protection capabilities, and a new service that simplifies the indexing of audio and video content and makes it easier to search….

Read More

Biotech Stock Abbvie can only Rise : here is why

In order to boost its pipeline, AbbVie Inc (ABBV) inked a collaboration agreement with Infinity Pharmaceuticals (INFI) to develop and commercialize the latter’s oncology candidate duvelisib (IPI-145). Infinity Pharma’s shares jumped over 44% following the announcement. AbbVie will be making an upfront payment of $275 million to Infinity Pharma to jointly commercialize duvelisib in the…

Read More